Reaction

Nail Discolouration reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 3,865 reports · 88 co-occurring drugs

As of the last recalculation, Nail Discolouration appears in 3,865 FAERS reports alongside 88 co-occurring drug terms. The strongest observed disproportionality signal is HYDROXYUREA (PRR 14.2).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Hydroxyurea	55	14.2	14.2
Pertuzumab	59	11.9	11.9
Terbinafine Hydrochloride	18	11.0	11.0
Rucaparib	16	9.8	9.8
Minocycline	20	9.3	9.3
Trastuzumab	112	9.0	9.0
Ado-Trastuzumab Emtansine	13	8.3	8.3
Niraparib	30	7.3	7.3
Lapatinib	18	6.3	6.3
Telmisartan	20	6.1	6.1
Anastrozole Tablets	23	5.8	5.8
Docetaxel Anhydrous	71	5.8	5.8
Docetaxel	71	5.8	5.8
Capecitabine	95	5.7	5.7
Paclitaxel (Aibumin-Bound)	84	5.6	5.6
Cabozantinib	49	5.5	5.6
Imatinib	18	5.5	5.5
Sunitinib Malate	38	5.2	5.3
Paclitaxel	94	5.2	5.2
Rosuvastatin Calcium	27	5.2	5.2
Anastrozole	35	5.2	5.2
Exemestane	19	4.8	4.8
Prochlorperazine Maleate	8	4.7	4.7
Minoxidil	38	4.6	4.6
Voxelotor	19	4.6	4.6
Avapritinib	10	4.5	4.5
Erlotinib	8	4.5	4.5
Abacavir Sulfate	8	4.4	4.4
Sirolimus	11	4.4	4.4
Panitumumab	12	4.1	4.1
Ribociclib	24	4.1	4.1
Osimertinib	24	4.1	4.1
Loperamide Hydrochloride And Dimethicone	24	4.1	4.1
Biotin	23	4.0	4.0
Lopinavir And Ritonavir	10	4.0	4.0
Fulvestrant	24	3.9	3.9
Erlotinib Hydrochloride	9	3.9	3.9
Letrozole Tablets	34	3.8	3.8
Chlorthalidone	8	3.7	3.7
Ruxolitinib	48	3.6	3.6
Zidovudine	9	3.6	3.6
Imatinib Mesylate	18	3.5	3.5
Carboxymethylcellulose Sodium	6	3.4	3.4
Palbociclib	60	3.4	3.4
Regorafenib	7	3.3	3.3
Bleomycin Sulfate	6	3.1	3.1
Sorafenib	12	3.1	3.1
Olaparib	12	3.1	3.1
Alpelisib	5	3.1	3.1
Dolutegravir Sodium	5	3.0	3.0
Cetuximab	17	2.9	2.9
Ritonavir 100 Mg	8	2.9	2.9
Ibrutinib	42	2.8	2.8
Lanreotide Acetate	4	2.7	2.8
Abemaciclib	10	2.7	2.7
Ixazomib	14	2.6	2.6
Secukinumab	74	2.5	2.5
Pazopanib Hydrochloride	12	2.4	2.4
Teriflunomide	20	2.4	2.4
Gefitinib	4	2.4	2.4
Omalizumab	37	2.4	2.4
Vemurafenib	5	2.2	2.2
Bevacizumab	50	2.2	2.2
Carboplatin	49	2.1	2.1
Nintedanib	12	2.1	2.1
Dasatinib	14	2.0	2.0
Ofatumumab	12	1.9	1.9
Axitinib	7	1.9	1.9
Enzalutamide	21	1.9	1.9
Naltrexone Hydrochloride And Bupropion Hydrochloride	3	1.9	1.9
Selinexor	3	1.9	1.9
Pembrolizumab	36	1.9	1.9
Minoxidil Foam 5% (Womens)	11	1.8	1.8
Risankizumab-Rzaa	26	1.7	1.7
Velpatasvir And Sofosbuvir	4	1.7	1.7
Lenvatinib	10	1.6	1.6
Encorafenib	3	1.6	1.6
Denosumab	61	1.6	1.6
Relugolix	7	1.6	1.6
Peginterferon Alfa-2A	16	1.6	1.6
Pegfilgrastim	29	1.6	1.6
Etanercept	170	1.6	1.6
Lenalidomide	117	1.5	1.5
Ixekizumab	7	1.0	1.0
Droxidopa	4	1.0	1.0
Abaloparatide	5	0.9	0.9
Apremilast	20	0.7	0.7
Dupilumab	62	0.7	0.7

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.